Emerging within the UK, retatrutide, a new compound , is sparking considerable interest within the scientific community regarding its promise for weight regulation. This dual GIP and GLP-1 receptor agonist looks to offer a significant advantage over existing therapies, showing encouraging results in early clinical assessments. Researchers believe i